Patient characteristics
A total of 110 patients were enrolled in this study. The median ages of the 110 patients and donors were 5.5 years (range 0.8-16.7 years) and 26.5 years (range 1-46 years), respectively. Fifty-seven patients received myeloablative conditioning (busulfan plus cyclophosphamide, total-body irradiation plus cyclophosphamide, or total-body irradiation plus cyclophosphamide and etoposide), and 53 patients received nonmyeloablative conditioning (fludarabine plus cyclophosphamide). All patients received PBSCT. Ninety-eight of the 110 patients were treated with antithymocyte globulin (ATG) during conditioning, and 61 patients were offered corticosteroid therapy (Table 1).